• Patients with progressive CRMPC who had castrate levels of testosterone for at least 1 year (by surgery or gonadotropin-releasing hormone analogs) received three times the standard replacement dose of testosterone
• Cohorts of 3–6 patients received testosterone for 1 week, 1 month, or until disease progression
• Toxicities, androgen levels, prostate-specific antigen (PSA) assays, computed tomography (CT) scans, bone scintigraphy, positron emission tomography (PET) scans, and metastatic tumor biopsy androgen receptor levels were assessed
Copyright © 